ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories total debt 1985–2026

Abbott Laboratories's total debt was 32.61B USD on 30 June 2026, up 142.7% on a year before. At the end of fiscal year 2025 it was 15.07B USD.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter30 Jun 202632.61B+142.67%5.60B-27.01B0.64
FY202531 Dec 202515.07B-1.36%8.94B-6.13B0.29
FY202431 Dec 202415.28B-3.77%7.97B-7.31B0.32
FY202331 Dec 202315.87B-11.55%7.28B-8.59B0.41
FY202231 Dec 202217.95B-6.78%10.17B-7.78B0.49
FY202131 Dec 202119.25B-3.21%10.25B-9.00B0.54
FY202031 Dec 202019.89B+4.14%7.15B-12.74B0.61
FY201931 Dec 201919.10B-2.39%4.14B-14.96B0.61
FY201831 Dec 201819.57B-29.93%4.09B-15.48B0.64
FY201731 Dec 201727.92B+26.89%9.61B-18.31B0.90
FY201631 Dec 201622.01B+144.48%18.78B-3.23B1.07
FY201531 Dec 20159.00B+14.96%6.13B-2.88B0.42
FY201431 Dec 20147.83B+19.34%4.46B-3.37B0.36
FY201331 Dec 20136.56B-67.96%8.10B1.54B0.26
FY201231 Dec 201220.48B+32.84%15.17B-5.30B0.77
FY201131 Dec 201115.41B-18.52%8.10B-7.32B0.63
FY201031 Dec 201018.92B+14.96%7.32B-11.59B0.83
FY200931 Dec 200916.46B+43.78%9.93B-6.52B0.71
FY200831 Dec 200811.45B-6.29%5.08B-6.37B0.65
FY200731 Dec 200712.21B-1.59%2.82B-9.39B0.69
FY200631 Dec 200612.41B+87.09%1.37B-11.04B0.88
FY200531 Dec 20056.63B-2.17%2.96B-3.68B0.46
FY200431 Dec 20046.78B+13.20%2.06B-4.72B0.47
FY200331 Dec 20035.99B-6.74%1.29B-4.70B0.46
FY200231 Dec 20026.42B-11.88%966.13M-5.46B0.60
FY200131 Dec 20017.29B+368.49%713.54M-6.58B0.80
FY200031 Dec 20001.56B-30.33%1.16B-399.10M0.18
FY199931 Dec 19992.23B-27.94%723.30M-1.51B0.30
FY199831 Dec 19983.10B+13.95%383.32M-2.72B0.54
FY199731 Dec 19972.72B+17.38%259.01M-2.46B0.54
FY199631 Dec 19962.32B+56.00%123.08M-2.19B0.48
FY199531 Dec 19951.49B+40.15%315.70M-1.17B0.34
FY199431 Dec 19941.06B-7.90%315.33M-744.27M0.26
FY199331 Dec 19931.15B+12.10%378.83M-771.61M0.31
FY199231 Dec 19921.03B+53.32%116.60M-909.70M0.31
FY199131 Dec 1991669.40M-16.18%60.40M-609.00M0.21
FY199031 Dec 1990798.60M+78.58%34.00M-764.60M0.28
FY198931 Dec 1989447.20M-46.93%13.60M-433.60M0.16
FY198831 Dec 1988842.60M-3.97%582.60M-260.00M0.34
FY198731 Dec 1987877.40M-1.32%519.90M-357.50M0.42
FY198631 Dec 1986889.10M+57.11%481.60M-407.50M0.50
FY198531 Dec 1985565.90M—437.50M-128.40M0.30

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Abbott Laboratories's debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.